Literature DB >> 33317243

Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease.

Karn Wijarnpreecha1, Elizabeth S Aby2, Aijaz Ahmed3, Donghee Kim3.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a multisystemic disease and a rapidly growing cause of chronic liver disease in children and adults worldwide. Diagnosis and management of extrahepatic manifestations of NAFLD, including cardiovascular disease (CVD), type 2 diabetes mellitus, metabolic syndrome, chronic kidney disease, obstructive sleep apnea, polycystic ovarian syndrome, hypothyroidism, psoriasis, and extrahepatic malignancy are crucial for the treatment of patients with NAFLD. The leading cause of death in NAFLD is primarily from CVD, followed by liver-related mortality, extrahepatic cancer, liver cancer, and diabetes-related mortality. Therefore, clinicians need to identify high-risk patients earlier in the disease course and be aware of the extrahepatic manifestations of NAFLD to improve liver disease outcomes. In this review, we focus on the monitoring and management of the extrahepatic manifestations of NAFLD.

Entities:  

Keywords:  Cardiovascular diseases; Fatty liver; Liver cirrhosis; Non-alcoholic fatty liver disease; Therapeutics

Year:  2020        PMID: 33317243     DOI: 10.3350/cmh.2020.0239

Source DB:  PubMed          Journal:  Clin Mol Hepatol        ISSN: 2287-2728


  4 in total

1.  Mouse liver injury induces hepatic macrophage FGF23 production.

Authors:  Pradeep Kumar; Yunshan Liu; Yang Shen; Jacquelyn J Maher; Francesca Cingolani; Mark J Czaja
Journal:  PLoS One       Date:  2022-03-01       Impact factor: 3.240

Review 2.  New Insights into Non-Alcoholic Fatty Liver Disease and Coronary Artery Disease: The Liver-Heart Axis.

Authors:  Georgiana-Diana Cazac; Cristina-Mihaela Lăcătușu; Cătălina Mihai; Elena-Daniela Grigorescu; Alina Onofriescu; Bogdan-Mircea Mihai
Journal:  Life (Basel)       Date:  2022-08-04

Review 3.  The Role of Resveratrol in Liver Disease: A Comprehensive Review from In Vitro to Clinical Trials.

Authors:  Carmine Izzo; Monica Annunziata; Giuseppe Melara; Roberta Sciorio; Marcello Dallio; Mario Masarone; Alessandro Federico; Marcello Persico
Journal:  Nutrients       Date:  2021-03-13       Impact factor: 5.717

4.  Fatty Liver Index for Predicting Nonalcoholic Fatty Liver Disease in an Asymptomatic Korean Population.

Authors:  Eun-Ju Cho; Gu-Cheol Jung; Min-Sun Kwak; Jong-In Yang; Jeong-Yoon Yim; Su-Jong Yu; Goh-Eun Chung
Journal:  Diagnostics (Basel)       Date:  2021-11-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.